Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.155
+0.135 (3.36%)
At close: Feb 6, 2026, 4:00 PM EST
4.150
-0.005 (-0.12%)
After-hours: Feb 6, 2026, 4:10 PM EST
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 56 employees as of December 31, 2024. The number of employees decreased by 19 or -25.33% compared to the previous year.
Employees
56
Change
-19
Growth
-25.33%
Revenue / Employee
n/a
Profits / Employee
-$2,625,446
Market Cap
324.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 56 | -19 | -25.33% |
| Sep 30, 2024 | 75 | 1 | 1.35% |
| Jun 30, 2024 | 75 | 3 | 4.17% |
| Mar 31, 2024 | 74 | 1 | 1.37% |
| Dec 31, 2023 | 75 | 5 | 7.14% |
| Sep 30, 2023 | 74 | 6 | 8.82% |
| Jun 30, 2023 | 72 | 9 | 14.29% |
| Mar 31, 2023 | 73 | 9 | 14.06% |
| Dec 31, 2022 | 70 | 11 | 18.64% |
| Sep 30, 2022 | 68 | 12 | 21.43% |
| Jun 30, 2022 | 63 | 14 | 28.57% |
| Mar 31, 2022 | 64 | 22 | 52.38% |
| Dec 31, 2021 | 59 | 20 | 51.28% |
| Sep 30, 2021 | 56 | 45 | 409.09% |
| Jun 30, 2021 | 49 | 38 | 345.45% |
| Mar 31, 2021 | 42 | 31 | 281.82% |
| Dec 31, 2020 | 39 | 28 | 254.55% |
| Jun 30, 2020 | 11 | - | - |
| Mar 31, 2020 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 299 |
| AC Immune | 172 |
| X4 Pharmaceuticals | 143 |
| Foghorn Therapeutics | 112 |
| Neumora Therapeutics | 95 |
| Armata Pharmaceuticals | 60 |
| PepGen | 57 |
| Cybin | 50 |
AVIR News
- 22 days ago - Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
- 6 weeks ago - Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript - Seeking Alpha
- 3 months ago - Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript - Seeking Alpha